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Background
Antiretroviral therapies including lopinavir (LPV) are
frequently associated with dyslipidemia. Atazanavir
(ATZ) and darunavir (DRV), currently recommended
new boosted protease inhibitor, seems to have a better
lipid profile than LPV, respectively in the Castle and
Artemis study.
Purpose of study
An observational study was conducted to evaluate the
benefit of switching LPV to ATZ or DRV on the lipid
results, and to compare the potency of DRV and ATZ
to enhance the lipid profiles.
Methods
Patients treated with LPV with undetectable viral load
since 6 months were switched to ATZ or DRV if they
have low density lipoprotein (LDL)>1.6 g/l with no
other cardiovascular risk, LDL>1.3g/l with at least 1 car-
diovascular risk, or high density lipoprotein (HDL)
<0.35mmo/l. None of the patients had an additional
lipid-lowering treatment since 3 months, and others
antiretroviral treatment wasn’t modified.
Results
Forty two patients were included (12 females and 30
males), mean age 45.7 years (25-65). At baseline mean
(SD) triglyceride (TG) level was 2.50g/l (1.64), total cho-
lesterol (TC) 2.14g/l (0.51), LDL 1.23g/l (0.42) and HDL
0.48g/l (0.17). The two groups (26 ATZ and 16 DRV)
were not different at baseline for weight, body mass
index, CD4, TG, TC, LDL and HDL. At month 12, none
of the 42 patients had virological failure but 1 patient in
the DRV group had his treatment switched to Atripla®
for simplification. There was a significant decrease in
TG and TC, -0.54g/l (1.06) (p<0.01) and -0.15g/l (0.41)
(p<0.05) respectively [mean (SD)]. In ATZ and DRV
group, the variation was respectively -0.33g/l (1.11) and
-0.91g/l (0.89) for TG (p=0.08), -0.17g/l (0.45) and
-0.12g/l (0.36) for TC (p=0.75), -0.08g/l (0.37) and
+0.04g/l (0.41) for LDL (p=0.47), +0.01g/l (0.11) and
+0.03g/l (0.10) for HDL.
Conclusion
In this observational study, switching LPV for ATZ or
DRV enhance the lipid profile. DRV has a trend to
reduce TG level more than ATZ.
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